Actively Recruiting
Evaluation of ONO-4538HSC for Pediatric Malignant Solid Tumors and Epithelioid Sarcoma A Multicenter Open-Label Phase III Study
Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-10-06
50
Participants Needed
15
Research Sites
117 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ONO-4538HSC, an investigational drug, in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma. This multicenter, open-label Phase III study aims to assess the drugs tolerability, safety, efficacy, and how it is processed in the body. The study includes patients who have tumors that are advanced, unresectable, or refractory to standard treatments. Participants will receive ONO-4538HSC as a subcutaneous injection once every 4 weeks. The study includes distinct groups pediatric patients aged 12 to under 18 years with malignant solid tumors, and patients aged 12 years and older with epithelioid sarcoma. The study explores tolerability in pediatric patients and the treatments effects in both groups over repeated cycles. During the trial, participants will be monitored for side effects, serious adverse events, and treatment response through clinical assessments over an average of 6 months. Blood samples will be taken to measure drug levels and tumor markers. Safety monitoring continues up to 100 days after the last dose. The study tracks various outcomes including response rate, progression-free survival, and duration of response to evaluate the drugs impact.
CONDITIONS
Brief Title
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Research Team
N
North America Clinical Trial Support Desk
I
International Clinical Trial Support Desk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here